Skye Bioscience (SKYE) news
Recent news
Skye Bioscience - enters $22 mln securities purchase agreement with Redmile Biopharma Investments III - SEC filing
Skye Bioscience, Inc. (Nasdaq: SKYE) has entered into a securities purchase agreement with Redmile Biopharma Investments III, a fund affiliated with Redmile, as part of a broader financing initiative tied to its pending merger with Redx Pharma. The agreement includes a committed equity line…
AInvest Wire · 6d agoSkye Bioscience: quarterly EPS $-0.27 - SEC filing
Skye Bioscience Inc. reported a quarterly earnings per share (EPS) loss of $-0.27 for the most recent quarter, as disclosed in a recent SEC filing [1]. The negative EPS reflects the company’s ongoing financial challenges, which include significant research and development expenditures typical of…
AInvest Wire · Aug 14, 2026Skye Bioscience - holders to receive CVR for 90% of Nimacimab net proceeds for 12 months post-closing
Skye Bioscience, Inc. (Nasdaq: SKYE) has announced that holders of its convertible debt will receive contingent value rights (CVRs) entitling them to 90% of the net proceeds from Nimacimab for a period of 12 months following the closing of a potential transaction. This arrangement is part of the…
AInvest Wire · Aug 14, 2026Skye Bioscience - combined company cash expected to fund operations into 2029 and RXC008 Phase 2 data in H2 2028
Skye Bioscience, Inc. (Nasdaq: SKYE) reported first-quarter 2026 financial results and business updates on May 12, 2026, indicating that its current cash, cash equivalents , and short-term investments totaled $17.1 million as of March 31, 2026. The company expects these funds to support operations…
AInvest Wire · Aug 14, 2026Skye Bioscience - Peter Collum to serve as CFO of Fibrx Therapeutics
Skye Bioscience has announced that Peter Collum will serve as Chief Financial Officer (CFO) of Fibrx Therapeutics, a clinical-stage biotechnology company focused on developing novel therapeutics for unmet medical needs. The appointment reflects Skye Bioscience’s ongoing commitment to strengthening…
AInvest Wire · Aug 14, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.